Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.

@article{Tchang2015MetreleptinAG,
  title={Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.},
  author={Beverly G. Tchang and Alpana P Shukla and Louis J. Aronne},
  journal={Expert opinion on biological therapy},
  year={2015},
  volume={15 7},
  pages={
          1061-75
        }
}
INTRODUCTION Metreleptin was recently approved by the Food and Drug Administration for the treatment of generalized lipodystrophy, a condition characterized by leptin deficiency. Its efficacy as hormone replacement therapy suggests broader applications in diseases also characterized by leptin abnormalities, such as familial partial lipodystrophy (FPLD), non-alcoholic fatty liver disease (NAFLD), and common obesity. Metreleptin, in conjunction with other pharmacologic interventions, has the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report

  • Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Obesity, Fat Mass and Immune System: Role for Leptin

  • Front. Physiol.
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 101 REFERENCES

Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.

  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2011
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.

  • The Journal of clinical endocrinology and metabolism
  • 2011
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL